Top 10 evidence-based essentials in rheumatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

By
Kathryn Wighton
November 3, 2026
5 min

MDSpire News

At a Glance

Category	Detail
Condition	Rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, gout, polymyalgia rheumatica, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and giant cell arteritis, as addressed by the cited guidelines, trials, and FDA labeling
Key Mechanisms	Disease-modifying and immunosuppressive therapy, glucocorticoid use and tapering, treat-to-target strategies, flare management, disease activity assessment, and fracture-risk estimation
Target Population	Patients covered by the cited guidelines, trials, FDA labeling, and assessment tools
Care Setting	Rheumatology disease management and treatment monitoring, plus fracture-risk assessment

Key Highlights

For rheumatoid arthritis, recommendations include initial methotrexate, ideally with short-term glucocorticoids, and adding a biologic DMARD if response is insufficient after 3 to 6 months.
The lupus and lupus nephritis guidelines emphasize hydroxychloroquine, limiting glucocorticoid duration, early immunosuppressive therapy, and individualized shared decision-making.
For gout, allopurinol is the preferred first-line urate-lowering therapy; dose titration is guided by serial serum urate measurements toward a target below 6 mg/dL.
In ORAL Surveillance, tofacitinib did not meet noninferiority criteria versus TNF inhibitors for major adverse cardiovascular events and cancers excluding nonmelanoma skin cancer in the studied population.
ACR-preferred rheumatoid arthritis activity measures support regular assessment, while FRAX estimates 10-year hip and major osteoporotic fracture probability.

Guideline-Based Recommendations

Diagnosis

Management

For patients with lupus nephritis who achieve a complete renal response, the described guideline approach includes pulse glucocorticoids followed by an oral taper and two additional immunosuppressive agents, with immunosuppressive treatment for at least 3 to 5 years.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

The source covers patients with specified rheumatic diseases and risk profiles, including adults with active psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, or giant cell arteritis; pediatric and adult patients with systemic lupus erythematosus; and trial populations described for rheumatoid arthritis and polymyalgia rheumatica.

SAPHYR enrolled patients with relapsing polymyalgia rheumatica during glucocorticoid tapering: sustained remission at 52 weeks was 28% with sarilumab and a 14-week prednisone taper versus 10% with placebo and a 52-week taper. Median cumulative glucocorticoid dose was 777 mg versus 2,044 mg. In the upadacitinib giant cell arteritis trial, 428 patients were randomized to 15 mg, 7.5 mg, or placebo, with corticosteroids as background therapy in all groups.

Clinical Best Practices

Apply treat-to-target strategies and use regular disease activity assessment in rheumatoid arthritis.
Discuss treatment decisions in light of each patient's clinical circumstances and preferences where the guidelines specify shared decision-making.
Assess relevant cardiovascular, malignancy, and thromboembolic risks before considering a JAK inhibitor for rheumatoid arthritis.
When initiating gout urate-lowering therapy, use anti-inflammatory prophylaxis for at least 3 to 6 months and titrate therapy using serial serum urate results.
Use FRAX with clinical risk factors and femoral neck bone mineral density to estimate 10-year fracture probability.